Henderson Equity Partners is a private equity firm that specializes in direct, secondary direct, and fund of fund investments, primarily focusing on the Asian market. The firm concentrates its efforts on growth equity and middle market investments across various sectors including alternative energy, financial services, healthcare, information technology, leisure, infrastructure, consumer products, real estate, logistics, media, retail, and telecommunications. In infrastructure, Henderson Equity Partners invests in social, transportation, and environmental projects, targeting areas such as education, health facilities, roads, street lighting, and waste management. Established in 1998 and headquartered in London, with additional offices in Singapore, Delhi, Munich, Hong Kong, and Beijing, the firm has a particular interest in Greater China and India for its Asian private equity investments. Henderson Equity Partners typically invests between $10 million and $30 million in growth equity and engages in public-private partnership projects in infrastructure. The firm is a subsidiary of Henderson Global Investors Limited.
Simba Sleep is a London-based company that designs and manufactures a range of sleep products, primarily focusing on mattresses. Founded in 2015, the company offers innovative mattresses that combine thousands of lightweight comfort springs with precision-engineered foam to enhance sleep quality. Simba Sleep's product line includes mattresses, pillows, duvets, bedding, and bed bases, utilizing a unique four-layer cooling foam system supported by patented conical pocket springs. The company emphasizes the importance of sleep and aims to help customers achieve better rest. Products are available through select retail partnerships, such as John Lewis, as well as via online sales, with financing options provided for customers.
Simba Sleep is a London-based company that designs and manufactures a range of sleep products, primarily focusing on mattresses. Founded in 2015, the company offers innovative mattresses that combine thousands of lightweight comfort springs with precision-engineered foam to enhance sleep quality. Simba Sleep's product line includes mattresses, pillows, duvets, bedding, and bed bases, utilizing a unique four-layer cooling foam system supported by patented conical pocket springs. The company emphasizes the importance of sleep and aims to help customers achieve better rest. Products are available through select retail partnerships, such as John Lewis, as well as via online sales, with financing options provided for customers.
Verona Pharma is a clinical-stage biopharmaceutical company headquartered in London, United Kingdom, that specializes in developing therapies for chronic respiratory diseases with significant unmet medical needs. The company's lead product candidate, ensifentrine, is an inhaled dual inhibitor of phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is currently in Phase 2b clinical development as a nebulized formulation for the maintenance treatment of chronic obstructive pulmonary disease (COPD), and alternative delivery methods, including a dry powder inhaler and a pressurized metered-dose inhaler, are also being explored. In addition to COPD, Verona Pharma aims to develop ensifentrine for other respiratory conditions such as cystic fibrosis and asthma. Founded in 2005, the company is committed to improving the health and quality of life for individuals affected by these challenging diseases.
Gartmore Group is an independent fund manager that specializes in asset management, offering a diverse range of investment products and services designed for both retail and institutional clients. The company is dedicated to delivering high alpha investment products and caters to a global clientele, including investors in the UK, Continental Europe, the U.S., Japan, and Latin America. By focusing solely on asset management, Gartmore aims to meet the varying investment needs of its clients through tailored solutions.
New Star Asset Management
Acquisition in 2009
New Star Asset Management is an investment management holding company. The company through its subsidiaries provides services in areas including UK investment funds, investment trusts, offshore funds/SICAVs, alternative investments, and Specialist institutional funds.
Sharda Cropchem Ltd is an agrochemical company based in India. It markets and sells formulations and active ingredients for agricultural purposes through its subsidiaries. The company functions through two segments, which are Agrochemicals, and Non Agrochemicals. The company earns a majority of its income through the development and sale of agrochemicals such as insecticides, herbicides, fungicides, and biocides. It sells conveyor belts, V-belts, timing belts, dyes, general chemicals. and dye intermediaries under the Non Agrochemicals segment. Geographically, it derives its key revenue is derived from Europe and the rest from the NAFTA countries, Latin America, India,more
Alaunos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies aimed at treating heterogeneous solid tumors. The company utilizes innovative platform technologies, including the Sleeping Beauty system, which enables the genetic engineering of immune cells to enhance T-cell functionality for cancer treatment. Alaunos is advancing several therapies, notably Ad-RTS-hIL-12 combined with veledimex, which is currently in Phase 2 trials for recurrent glioblastoma multiforme. Additionally, the company is exploring chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies, leveraging collaborations with renowned institutions such as MD Anderson Cancer Center. The RheoSwitch Therapeutic System is another key technology employed by Alaunos, allowing for precise modulation of gene expression to improve cancer treatment outcomes. Founded in 1998 and based in Boston, Massachusetts, Alaunos is committed to advancing its portfolio of immuno-oncology solutions to address unmet medical needs in cancer care.
Alaunos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies aimed at treating heterogeneous solid tumors. The company utilizes innovative platform technologies, including the Sleeping Beauty system, which enables the genetic engineering of immune cells to enhance T-cell functionality for cancer treatment. Alaunos is advancing several therapies, notably Ad-RTS-hIL-12 combined with veledimex, which is currently in Phase 2 trials for recurrent glioblastoma multiforme. Additionally, the company is exploring chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies, leveraging collaborations with renowned institutions such as MD Anderson Cancer Center. The RheoSwitch Therapeutic System is another key technology employed by Alaunos, allowing for precise modulation of gene expression to improve cancer treatment outcomes. Founded in 1998 and based in Boston, Massachusetts, Alaunos is committed to advancing its portfolio of immuno-oncology solutions to address unmet medical needs in cancer care.
Homann Feinkost GmbH, founded in 1876 and based in Dissen, Germany, specializes in producing a variety of chilled food products, including mayonnaise, salad dressings, bread dips, and seafood buffets. The company caters to both retail and food service markets, offering a diverse range of items suitable for various occasions, such as grilling and snacking. As of April 2015, Homann operates as a subsidiary of Gastronomia y Negocios S.A., furthering its reach in the fine dining sector.
Wellnet SpA
Acquisition in 2004
Italian fitness and wellness chain
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.